Adamis Pharmaceuticals Corporation (ADMP): Price and Financial Metrics


Adamis Pharmaceuticals Corporation (ADMP): $0.45

0.02 (+3.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ADMP POWR Grades


  • Growth is the dimension where ADMP ranks best; there it ranks ahead of 59.83% of US stocks.
  • ADMP's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • ADMP's current lowest rank is in the Quality metric (where it is better than 1.51% of US stocks).

ADMP Stock Summary

  • The ratio of debt to operating expenses for Adamis Pharmaceuticals Corp is higher than it is for about merely 6.31% of US stocks.
  • With a year-over-year growth in debt of -80.35%, Adamis Pharmaceuticals Corp's debt growth rate surpasses only 3.05% of about US stocks.
  • Revenue growth over the past 12 months for Adamis Pharmaceuticals Corp comes in at -42.77%, a number that bests only 3.8% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ADMP, based on their financial statements, market capitalization, and price volatility, are NTUS, CTS, FOXF, KIQ, and IRIX.
  • Visit ADMP's SEC page to see the company's official filings. To visit the company's web site, go to www.adamispharmaceuticals.com.

ADMP Valuation Summary

  • ADMP's price/sales ratio is 9.8; this is 13.66% lower than that of the median Healthcare stock.
  • Over the past 243 months, ADMP's price/sales ratio has gone down 86.8.
  • ADMP's price/earnings ratio has moved up 3.4 over the prior 243 months.

Below are key valuation metrics over time for ADMP.

Stock Date P/S P/B P/E EV/EBIT
ADMP 2021-08-31 9.8 46.4 -3.3 -3.3
ADMP 2021-08-30 9.5 44.7 -3.2 -3.2
ADMP 2021-08-27 9.8 46.4 -3.3 -3.3
ADMP 2021-08-26 9.7 46.0 -3.3 -3.3
ADMP 2021-08-25 10.0 47.3 -3.3 -3.4
ADMP 2021-08-24 10.2 48.1 -3.4 -3.4

ADMP Growth Metrics

    Its 2 year price growth rate is now at -85.1%.
  • Its 5 year cash and equivalents growth rate is now at 137.32%.
  • Its 4 year net cashflow from operations growth rate is now at -33.96%.
Over the past 37 months, ADMP's revenue has gone down $1,257,439.

The table below shows ADMP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 12.51713 -36.52327 -57.42382
2020-12-31 16.5274 -20.90136 -49.39109
2020-09-30 18.43029 -18.42784 -34.70541
2020-06-30 20.03275 -16.57601 -34.21996
2020-03-31 21.87131 -15.85191 -30.69283
2019-12-31 22.11387 -19.88567 -29.30677

ADMP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADMP has a Quality Grade of F, ranking ahead of 1.65% of graded US stocks.
  • ADMP's asset turnover comes in at 0.414 -- ranking 112th of 682 Pharmaceutical Products stocks.
  • ELTP, XENE, and LPTX are the stocks whose asset turnover ratios are most correlated with ADMP.

The table below shows ADMP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.414 0.099 -4.946
2020-09-30 0.417 0.120 -2.753
2020-06-30 0.432 0.173 -2.533
2020-03-31 0.453 0.289 -2.096
2019-12-31 0.441 0.300 -1.898
2019-09-30 0.393 0.309 -2.593

ADMP Price Target

For more insight on analysts targets of ADMP, see our ADMP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.25 Average Broker Recommendation 2 (Hold)

ADMP Stock Price Chart Interactive Chart >

Price chart for ADMP

ADMP Price/Volume Stats

Current price $0.45 52-week high $1.48
Prev. close $0.44 52-week low $0.31
Day low $0.42 Volume 361,500
Day high $0.46 Avg. volume 1,209,722
50-day MA $0.43 Dividend yield N/A
200-day MA $0.69 Market Cap 68.07M

Adamis Pharmaceuticals Corporation (ADMP) Company Bio


Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.


ADMP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMP Latest Social Stream


Loading social stream, please wait...

View Full ADMP Social Stream

Latest ADMP News From Around the Web

Below are the latest news stories about Adamis Pharmaceuticals Corp that investors may wish to consider to help them evaluate ADMP as an investment opportunity.

Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today announced that the compensation committee of the board of directors and the company’s independent directors approved the grant of stock options on February 15, 2022, to purchase an aggregate of 1

Yahoo | February 18, 2022

Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now examine clinical and safety data from the first 50 subjects as part of the first interim analysis. COVID-19 is a complex disease that manifests in multiple phases including, among others, viral replication

Yahoo | February 7, 2022

Adamis Pharma Updates 1 Key Risk Factor

3 clinical trial in patients affected by COVID-19. Importantly, Tempol has demonstrated antiviral, anti-inflammatory, and antioxidant activity. While there have been recent approvals for oral antiviral drugs, Adamis noted Tempol’s unique mechanism of action and safety profile would offer an unmet medical requirement. With this development in mind, let us take a look at the changes in Adamis’ key risk factors that investors should know.

Kailas Salunkhe on TipRanks | January 12, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | January 11, 2022

Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?

NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com

Benzinga | January 10, 2022

Read More 'ADMP' Stories Here

ADMP Price Returns

1-mo 0.72%
3-mo -25.00%
6-mo -28.24%
1-year -63.41%
3-year -65.38%
5-year -91.35%
YTD -25.62%
2021 24.72%
2020 -30.74%
2019 -68.87%
2018 -48.86%
2017 39.68%

Continue Researching ADMP

Here are a few links from around the web to help you further your research on Adamis Pharmaceuticals Corp's stock as an investment opportunity:

Adamis Pharmaceuticals Corp (ADMP) Stock Price | Nasdaq
Adamis Pharmaceuticals Corp (ADMP) Stock Quote, History and News - Yahoo Finance
Adamis Pharmaceuticals Corp (ADMP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5631 seconds.